|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...6162636465666768697071...156157» |
- ||| New trial: EJB046: The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans (clinicaltrials.gov) - Jul 6, 2015
P=N/A, N=80, Recruiting, Sponsor: University of Virginia
- | New P2 trial: Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 6, 2015
P2, N=30, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: ACT-MOVE: A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (clinicaltrials.gov) - Jul 6, 2015
P3, N=162, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting
- Enrollment open: Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis (clinicaltrials.gov) - Jul 3, 2015
P=N/A, N=25, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial suspension, Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=15, Suspended, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Suspended | Trial primary completion date: Jun 2015 --> Jun 2016
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2015
P3, N=100, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended | Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Orencia (abatacept) / BMS
Trial completion: ACCLAIM: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2015
P2, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Jul 2, 2015
P4, N=429, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Jan 2015 --> Jun 2015
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=95, Terminated, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> Jun 2015 Trial primary completion date: Mar 2012 --> Mar 2015
- New P2 trial: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 2, 2015
P2, N=40, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- ||| Enrollment open: Insight Kids: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=98, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2012 --> Mar 2015 Active, not recruiting --> Recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926 (clinicaltrials.gov) - Jul 2, 2015
P3, N=13, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | ADL5859 / Pfizer
Enrollment change: Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 1, 2015
P2, N=46, Completed, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Completed N=60 --> 46
- |||||||||| CHS-0214 (etanercept biosimilar) / Coherus Biosci
New P3 trial: A Long Term Safety Extension Study (CHS-0214-05) (clinicaltrials.gov) - Jul 1, 2015
P3, N=400, Not yet recruiting, Sponsor: Coherus Biosciences, Inc.
- ||| New trial: Validation of Standardized Questionnaires on Depression for Rheumatoid Arthritis (RA) (VADERA I) and Investigation of the Frequency of Depression in RA (VADERA II) (clinicaltrials.gov) - Jun 30, 2015
P=N/A, N=1300, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| dalfampridine / Generic mfg.
Enrollment closed, Enrollment change: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2015
P3, N=101, Active, not recruiting, Sponsor: Biogen
N=60 --> 46 Recruiting --> Active, not recruiting | N=128 --> 101
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Jun 30, 2015
P1, N=22, Not yet recruiting, Sponsor: Sanofi
- || smart insulin (MK-2640) / Merck (MSD)
Enrollment closed: A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) (clinicaltrials.gov) - Jun 30, 2015
P1, N=58, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=128 --> 101 Recruiting --> Active, not recruiting
- Trial primary completion date: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jun 29, 2015
P2, N=80, Recruiting, Sponsor: Academic MS Center Limburg
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jul 2016
- || atacicept (VT-001) / Vera Therap
Trial primary completion date: Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) (clinicaltrials.gov) - Jun 29, 2015
P2b, N=213, Recruiting, Sponsor: EMD Serono
Trial primary completion date: Mar 2015 --> Jul 2016 Trial primary completion date: May 2016 --> Apr 2018
- ||| atacicept (VT-001) / Vera Therap
Enrollment change: ADDRESS II: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 29, 2015
P2b, N=521, Recruiting, Sponsor: EMD Serono
Trial primary completion date: May 2016 --> Apr 2018 N=279 --> 521
- | andecaliximab (GS-5745) / Gilead
Trial completion, P1 data, PK/PD data: Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 29, 2015
P1, N=18, Completed, Sponsor: Gilead Sciences
N=279 --> 521 Active, not recruiting --> Completed
- Trial primary completion date: APPEL4: Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=12, Active, not recruiting, Sponsor: J.H. DeVries
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Sep 2015
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: ESCALATE: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (clinicaltrials.gov) - Jun 29, 2015
P4, N=130, Recruiting, Sponsor: Biogen
Trial primary completion date: Oct 2014 --> Sep 2015 N=200 --> 130
- omeprazole / Generic mfg., cyclosporine / Generic mfg.
Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) - Jun 29, 2015
P2b, N=81, Not yet recruiting, Sponsor: Perle Bioscience, Inc.
N=200 --> 130 Phase classification: P3 --> P2b | N=130 --> 81 | Initiation date: Feb 2015 --> Aug 2015 | Trial primary completion date: Nov 2015 --> May 2016
- New P1 trial: 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 29, 2015
P1, N=30, Not yet recruiting, Sponsor: North Shore Long Island Jewish Health System
- ||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Enrollment open, Trial initiation date, Patient reported outcomes: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=240, Recruiting, Sponsor: Biogen
Phase classification: P3 --> P2b | N=130 --> 81 | Initiation date: Feb 2015 --> Aug 2015 | Trial primary completion date: Nov 2015 --> May 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015
- Trial primary completion date: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2015
P3, N=600, Active, not recruiting, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015 Trial primary completion date: Sep 2017 --> Dec 2015
- Biomarker, Enrollment change: Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=110, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial primary completion date: Sep 2017 --> Dec 2015 N=170 --> 110
- Enrollment open, Trial primary completion date: GADD34-LES: Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=250, Recruiting, Sponsor: University Hospital, Grenoble
N=170 --> 110 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Jun 2018
- Trial completion, Enrollment change: Pilot Study of Ultrasound in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=17, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Jun 2018 Recruiting --> Completed | N=30 --> 17
- ||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: TENERE: A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2015
P3, N=324, Completed, Sponsor: Sanofi
Recruiting --> Completed | N=30 --> 17 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=20, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date, Metastases: Effect of Structured Nutrition Education in Type 1 Diabetes (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=216, Active, not recruiting, Sponsor: G
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Nov 2015
- leramistat (MBS2320) / Istesso, J&J
New P1 trial: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 25, 2015
P1, N=108, Not yet recruiting, Sponsor: Modern Biosciences plc
- New trial, HEOR: Joint Fitness: Exercise and Body Composition in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jun 24, 2015
P=N/A, N=0, Recruiting, Sponsor: Johns Hopkins University
- |||||||||| Abrilada (adalimumab-afzb) / Pfizer
New P3 trial, Combination therapy: A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). (clinicaltrials.gov) - Jun 24, 2015
P3, N=560, Not yet recruiting, Sponsor: Pfizer
- ||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed, Review, Compliance: Go-Compl-Ar: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab (clinicaltrials.gov) - Jun 24, 2015
P4, N=113, Active, not recruiting, Sponsor: Janssen-Cilag, S.A.
Trial primary completion date: May 2015 --> Nov 2015 Not yet recruiting --> Active, not recruiting
- || Betaseron (IFN-β-1b) / Bayer
Enrollment closed, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Jun 24, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| atorvastatin / Generic mfg.
Trial primary completion date: AdDIT: Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (clinicaltrials.gov) - Jun 24, 2015
P3, N=500, Active, not recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Mar 2016
- rosuvastatin / Generic mfg.
Trial completion, Enrollment change: A Trial of Rosuvastatin in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 23, 2015
P2, N=33, Completed, Sponsor: Imperial College London
Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | N=60 --> 33
- | Victoza (liraglutide) / Novo Nordisk
Trial completion: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting (clinicaltrials.gov) - Jun 23, 2015
P1, N=15, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Active, not recruiting --> Completed | N=60 --> 33 Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Sitagliptin Dose Determination Study (clinicaltrials.gov) - Jun 23, 2015
P4, N=7, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Recruiting --> Completed Recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2015
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Trial completion, Trial primary completion date: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (clinicaltrials.gov) - Jun 23, 2015
P4, N=35, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014
- Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
New trial: Long-term Immunogenicity of a HPV Vaccine in SLE (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Tuen Mun Hospital
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: TYGRIS: TYSABRI Global Observational Program in Safety (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=2207, Completed, Sponsor: Biogen
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=36, Completed, Sponsor: Nationwide Children's Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=54 --> 36
- ||| New trial: Impact of Vasculitis on Employment and Income (clinicaltrials.gov) - Jun 20, 2015
P=N/A, N=400, Recruiting, Sponsor: University of South Florida
- leucovorin calcium / Generic mfg.
Trial suspension: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jun 20, 2015
P2, N=192, Suspended, Sponsor: University of Arkansas
Recruiting --> Completed | N=54 --> 36 Recruiting --> Suspended